Clinical Observation of Recombinant Human Growth Hormone Injection Assisted IVF-ET in the Treatment of PCOS
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02801565|
Recruitment Status : Unknown
Verified June 2016 by GeneScience Pharmaceuticals Co., Ltd..
Recruitment status was: Recruiting
First Posted : June 16, 2016
Last Update Posted : November 28, 2016
|Condition or disease||Intervention/treatment||Phase|
|Polycystic Ovary Syndrome||Drug: Conventional controlled ovarian stimulation proctol||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||208 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Clinical Observation of Recombinant Human Growth Hormone Injection Assisted in Vitro Fertilization and Embryo Transfer (IVF-ET) in the Treatment of Polycystic Ovary Syndrome (PCOS)|
|Study Start Date :||February 2016|
|Estimated Primary Completion Date :||February 2017|
Experimental: GH AQ
Controlled ovarian stimulation in the middle of the corpus (D21 days) of the previous menstrual cycle to use recombinant Human Growth Hormone Injection（rhGH） Injection 15IU/5mg/3mL/cartridge, 5IU per day, Subcutaneous injection after 20:00 until the HCG trigger day.
Drug: Conventional controlled ovarian stimulation proctol
Conventional controlled ovarian stimulation proctol without rhGH.
- Clinical pregnancy rate [ Time Frame: One year ]
- Number of fertilized oocytes [ Time Frame: One year ]
- Number of retrieved oocytes [ Time Frame: One year ]
- Number of high quality embryos [ Time Frame: One year ]
- Number of transferred embryos [ Time Frame: One year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02801565
|Contact: Shuo Huangfirstname.lastname@example.org|
|Peking University Third Hospital||Recruiting|
|Contact: Ying Wang 010-82265080|
|Principal Investigator:||Ying Wang||Peking University Third Hospital|